公开(公告)号：US11655289B2

公开(公告)日：2023-05-23

申请号：US16639338

申请日：2018-08-22

Applicant: Biogen MA Inc.

Inventor： Steven Andrew Lantz ,  Kapil Gupta ,  Shantanu Sule ,  Adnan Zunic

IPC: A61K39/395 ,  C07K16/18 ,  A61K47/18 ,  A61K47/20 ,  A61K47/22 ,  A61K47/26 ,  A61K39/00

CPC classification number: C07K16/18 ,  A61K39/3955 ,  A61K39/39591 ,  A61K47/183 ,  A61K47/20 ,  A61K47/22 ,  A61K47/26 ,  A61K2039/505 ,  C07K2317/565 ,  C07K2317/94

Abstract: Pharmaceutical compositions containing anti-beta amyloid (Aβ) antibodies or AD-binding fragments thereof are provided. These pharmaceutical compositions find use in the treatment of abnormal accumulation or deposition of Aβ in the central nervous system, mild cognitive impairment, and AD-associated disorders such as Alzheimer's disease.

公开(公告)号：US20240043513A1

公开(公告)日：2024-02-08

申请号：US18300339

申请日：2023-04-13

Applicant: Biogen MA Inc.

Inventor： Steven Andrew Lantz ,  Kapil Gupta ,  Shantanu Sule ,  Adnan Zunic

IPC: C07K16/18 ,  A61K39/395 ,  A61K47/18 ,  A61K47/20 ,  A61K47/22 ,  A61K47/26

CPC classification number: C07K16/18 ,  A61K39/3955 ,  A61K39/39591 ,  A61K47/183 ,  A61K47/20 ,  A61K47/22 ,  A61K47/26 ,  A61K2039/505

Abstract: Pharmaceutical compositions containing anti-beta amyloid (Aβ) antibodies or Aβ-binding fragments thereof are provided. These pharmaceutical compositions find use in the treatment of abnormal accumulation or deposition of Aβ in the central nervous system, mild cognitive impairment, and Aβ-associated disorders such as Alzheimer's disease.

公开(公告)号：US20210188954A1

公开(公告)日：2021-06-24

申请号：US16639338

申请日：2018-08-22

Applicant: Biogen MA Inc.

Inventor： Steven Andrew Lantz ,  Kapil Gupta ,  Shantanu Sule ,  Adnan Zunic

IPC: C07K16/18 ,  A61K39/395 ,  A61K47/18 ,  A61K47/26 ,  A61K47/22 ,  A61K47/20

Abstract: Pharmaceutical compositions containing anti-beta amyloid (Aβ) antibodies or AD-binding fragments thereof are provided. These pharmaceutical compositions find use in the treatment of abnormal accumulation or deposition of Aβ in the central nervous system, mild cognitive impairment, and AD-associated disorders such as Alzheimer's disease.